ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

When Ipsen announced last week that it wanted in on Exelixis' Cabometyx for thyroid cancer, the company pegged that move to the oncology drug's promising late-stage trial results. Now, Exelixis is offering up more details of that very trial.